Zydus Life bags USFDA orphan drug tag for Desidustat indicated for sickle cell disease treatment

February 6, 2026
Uncategorized

Zydus Lifesciences received USFDA Orphan Drug Designation for Desidustat to treat Sickle Cell Disease, with incentives and study data pending publication.

Zydus Life bags USFDA orphan drug tag for Desidustat indicated for sickle cell disease treatment

Leave a ReplyCancel Reply

Explained — Why the latest RBI announcement is positive for Manappuram and Muthoot Finance

Poly Medicure shares decline 7% after Q3 profit and margins take a hit

CESC Q3 EBITDA rises 28%, margins expand to 20.1%

BEML Q3 Results: PSU Stock slides 10% after net loss; operating profit nearly wiped out

Siemens Results: New orders jump 19%, lift revenue growth; margin softens